Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

摘要: This multicenter study assesses the value of O(6)-methylguanine-DNA methyltransferase (MGMT) status for predicting overall survival in glioblastoma patients. Five methods are used, to identify approach with best prognostic value. Eighty-one tumors were obtained from patients glioblastomas treated by surgery and radiotherapy concomitant temozolomide (TMZ) followed adjuvant TMZ. MGMT promoter methylation was assessed qualitative methyl-specific polymerase chain reaction (MSP), semiquantitative (SQ-MSP), pyrosequencing, while expression measured at RNA level quantitative real-time PCR (Q-RT-PCR) protein immunohistochemistry (IHC). as evaluated MSP, SQ-MSP, pyrosequencing significantly correlated survival. The predictive one specific CpG position. Overall 14 25 months percentages below above median, respectively. In contrast, determined Q-RT-PCR IHC showed little or no correlation survival, These results confirm initially SQ-MSP allowed better discrimination than classical represented a good option.